The emergence of new therapies for Chronic Pain Associated with Painful Diabetic Neuropathy is anticipated to drive significant growth in the market over the coming years.
DelveInsight has launched a new report on “Chronic Pain Associated with Painful Diabetic Neuropathy – Market Insights, Epidemiology, and Market Forecast-2034” that delivers an in-depth understanding of the Chronic Pain Associated with Painful Diabetic Neuropathy, historical and forecasted epidemiology as well as the Chronic Pain Associated with Painful Diabetic Neuropathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Download sample pages on our chronic pain associated with painful diabetic neuropathy market
Some of the key facts of the Chronic Pain Associated with Painful Diabetic Neuropathy Market Report:
-
According to DelveInsight, the Chronic Pain Associated with Painful Diabetic Neuropathy (PDN) market is expected to experience steady growth between 2023 and 2034, fueled by the introduction of novel therapies and the rising prevalence of cases. Key players such as AstraZeneca, Regenacy Pharmaceuticals, Nevro Corp., and Erchonia Corporation are actively developing treatments within this space.
-
The National Health Service reports that roughly 21–25% of people with diabetes in the UK suffer from painful diabetic neuropathy. While the development pipeline for PDN-related chronic pain remains relatively limited, several promising therapies are progressing toward commercialization. These include MEDI7352 (AstraZeneca), Ricolinostat (Regenacy Pharmaceuticals), SCS HF10 Technology (Nevro Corp.), and Erchonia® EVRL™ (Erchonia Corporation).
-
In 2022, the FDA approved spinal cord stimulation (SCS) devices for managing chronic, intractable pain associated with PDN. Notably, the Vanta™ system delivers low-frequency stimulation with a battery life of approximately 11 years, while the Intellis™ system offers high-frequency stimulation with transcutaneous recharge capability within an hour.
-
Earlier, in July 2021, the FDA approved Nevro’s 10 kHz high-frequency SCS therapy for PDN, following the SENZA-PDN randomized controlled trial, which demonstrated significant pain relief and improvements in patients’ quality of life.
-
These advancements signal a growing focus on both pharmacological and device-based interventions, which are poised to reshape the treatment landscape for chronic pain in PDN.
Key benefits of the Chronic Pain Associated with Painful Diabetic Neuropathy market report:
-
Chronic Pain Associated with Painful Diabetic Neuropathy market report covers a descriptive overview and comprehensive insight of the Chronic Pain Associated with Painful Diabetic Neuropathy Epidemiology and Chronic Pain Associated with Painful Diabetic Neuropathy market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
-
The Chronic Pain Associated with Painful Diabetic Neuropathy market report provides insights on the current and emerging therapies.
-
Chronic Pain Associated with Painful Diabetic Neuropathy market report provides a global historical and forecasted market covering drug outreach in 7MM.
-
The Chronic Pain Associated with Painful Diabetic Neuropathy market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Chronic Pain Associated with Painful Diabetic Neuropathy market.
Got queries? Click here to know more about the Chronic Pain Associated with Painful Diabetic Neuropathy Market Landscape
Chronic Pain Associated with Painful Diabetic Neuropathy Overview
Chronic pain associated with Painful Diabetic Neuropathy (PDN) is a debilitating condition impacting millions globally. As a serious complication of diabetes, it substantially diminishes patients’ quality of life. The condition arises from nerve damage, primarily affecting the peripheral nervous system, and leads to persistent pain, most often in the extremities. Although the exact mechanisms linking diabetes to nerve injury are not fully understood, prolonged exposure to elevated blood glucose levels is considered a major contributing factor.
PDN affects roughly 25% of diabetic patients in clinical settings and has a profound effect on daily functioning. Patients often experience burning pain, numbness, and abnormal sensations (paresthesias), typically following a stocking-glove pattern—beginning in the feet and hands and gradually progressing toward the upper limbs and legs.
Chronic Pain Associated with Painful Diabetic Neuropathy Market Outlook
The Chronic Pain Associated with Painful Diabetic Neuropathy market is expected to evolve over the coming years, driven by the anticipated introduction of new therapies from leading companies including AstraZeneca, Regenacy Pharmaceuticals, Nevro Corp., Erchonia Corporation, and others between 2020 and 2034.
Discover how the chronic pain associated with diabetic neuropathy market is rising
Chronic Pain Associated with Painful Diabetic Neuropathy Therapies and Key Companies
-
MEDI7352 (AstraZeneca)
-
Ricolinostat (Regenacy Pharmaceuticals)
-
SCS HF10 Technology (Nevro Corp.)
-
Erchonia® EVRL™ (Erchonia Corporation), are in progress and anticipated to enter the market soon.
Scope of the Chronic Pain Associated with Painful Diabetic Neuropathy Market Report
-
Study Period: 2020-2034
-
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
-
Key Chronic Pain Associated with Painful Diabetic Neuropathy Companies: AstraZeneca, Regenacy Pharmaceuticals, Nevro Corp., Erchonia Corporation, and others
-
Chronic Pain Associated with Painful Diabetic Neuropathy Therapeutic Assessment: Chronic Pain Associated with Painful Diabetic Neuropathy current marketed and Chronic Pain Associated with Painful Diabetic Neuropathy emerging therapies
-
Chronic Pain Associated with Painful Diabetic Neuropathy Market Dynamics: Chronic Pain Associated with Painful Diabetic Neuropathy market drivers and Chronic Pain Associated with Painful Diabetic Neuropathy market barriers
-
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
-
Chronic Pain Associated with Painful Diabetic Neuropathy Unmet Needs, KOL’s views, Analyst’s views, Chronic Pain Associated with Painful Diabetic Neuropathy Market Access and Reimbursement
Request sample pages @ https://www.delveinsight.com/sample-request/chronic-pain-associated-with-painful-diabetic-neuropathy-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Table of Contents
1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Chronic Pain Associated with Painful Diabetic Neuropathy Patient Share (%) Overview at a Glance
5. Chronic Pain Associated with Painful Diabetic Neuropathy Market Overview at a Glance
6. Chronic Pain Associated with Painful Diabetic Neuropathy Disease Background and Overview
7. Chronic Pain Associated with Painful Diabetic Neuropathy Epidemiology and Patient Population
8. Country-Specific Patient Population of Chronic Pain Associated with Painful Diabetic Neuropathy
9. Chronic Pain Associated with Painful Diabetic Neuropathy Current Treatment and Medical Practices
10. Unmet Needs
11. Chronic Pain Associated with Painful Diabetic Neuropathy Emerging Therapies
12. Chronic Pain Associated with Painful Diabetic Neuropathy Market Outlook
13. Country-Wise Chronic Pain Associated with Painful Diabetic Neuropathy Market Analysis (2020–2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Chronic Pain Associated with Painful Diabetic Neuropathy Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Click here to read more about Chronic Pain Associated with Painful Diabetic Neuropathy Market Outlook 2034
Related Reports:
Chronic Pain Associated with Painful Diabetic Neuropathy Pipeline Insights, DelveInsight
“Chronic Pain Associated with Painful Diabetic Neuropathy Pipeline Insight, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Chronic Pain Associated with Painful Diabetic Neuropathy market. A detailed picture of the Chronic Pain Associated with Painful Diabetic Neuropathy pipeline landscape is provided, which includes the disease overview and Chronic Pain Associated with Painful Diabetic Neuropathy treatment guidelines.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/